Navigation Links
Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
Date:10/19/2007

- MAXIMA findings in The Lancet affirm the maintenance of hemoglobin levels

with less frequent dosing -

NUTLEY, N.J., Oct. 19 /PRNewswire/ -- A pivotal study published today in The Lancet has shown that dialysis patients were effectively switched from frequently-dosed anemia drugs to an innovative investigational anemia treatment, MIRCERA(R), administered up to once every four weeks(1)

The MAXIMA study is the first randomized, comparative study to investigate the direct conversion of dialysis patients with chronic kidney disease from treatment with erythropoiesis-stimulating agents (ESA) given one to three times a week to IV MIRCERA administered once every two weeks or once every four weeks. The results demonstrated that MIRCERA maintained hemoglobin (Hb) concentrations within the target range as effectively as ESAs epoetin alfa or beta, which are typically given three times a week.

"Our findings demonstrate that MIRCERA was administered up to once every four weeks in hemodialysis patients without sacrificing hemoglobin stability," said Nathan Levin, M.D., Medical and Research Director, Renal Research Institute, New York, New York, and the lead author of the publication. "We note in The Lancet that these results should be generalizable to the maintenance hemodialysis population and that we believe this drug should be an option to epoetin for simplified anemia management."

About the MAXIMA Study

The MAXIMA study randomized 673 adult patients with stable chronic renal anemia on dialysis therapy and IV maintenance epoetin at 91 centers in eight countries. Most patients were from North America (U.S. - 68 percent; Canada - 11 percent) and Europe (21 percent). The study compared two administration intervals of IV MIRCERA (once every two weeks or once every four weeks) with continued IV epoetin treatment (one to three-times a week) in patients with chronic renal anemia. After a run-in period, patients were randoml
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Adeptus Health Inc. (NYSE: ADPT ) (the ... the previously announced offering of 2,100,000 shares of its ... to be sold by the Company, and 750,329 shares ... Partners (the "Selling Stockholder"), at a price to the ... and the Selling Stockholder have granted the underwriters an ...
(Date:5/5/2015)... BOSTON , May 5, 2015   InspireMD, Inc. ... in embolic protection systems, announced today that it will release ... 31, 2015 on Monday, May 11 th before the ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6
(Date:5/5/2015)... (PRWEB) May 05, 2015 With the FCPX ... can quickly and easily add washed color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 90 washed CUBE LUT files. , This ... Monochromatic can give any footage a washed look. , ...
(Date:5/5/2015)... 2015 Private equity consultant and international ... announced that its dental stem cell biobank project, ... again--in April, 2015 –and posted yet another exciting record. ... volume and represents a significant 54% increase over last ... biobank is conducted via the Store-A-Tooth brand. The company ...
(Date:5/5/2015)... Beverly Hills Cosmetic Dentist, Arthur Glosman released a luxury ... sold at the offices of Arthur Glosman DDS, 450 N ... an online store . “I wanted to be one ... care and beauty with a luxurious collection of products designed ... , Dr. Glosman’s Advanced Dental Health + Beauty™ products ...
(Date:5/5/2015)... NCPDP announced today that AmerisourceBergen ... a three-year commitment of strategic support for NCPDP, and ... “AmerisourceBergen has supported our multi-stakeholder forum over 3 decades,” ... is a wonderful continuation and expansion of its commitment ... back to our very first Board of Trustees in ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), ... billion peripheral nerve repair market, reported record revenue of ... 2015 compared to $3.14 million in the year-ago first ... proprietary portfolio of nerve repair products - Avance® ... – and our solid sales execution delivered another record ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... to Nutrition experts, some new ways of getting the ... that omega-6 fatty acids are associated with chronic diseases, ... regular daily diet naturally// includes some of each. ... your omega-3s from fish like sardines, salmon and tuna. ...
... spend more for health care and medications than smokers, ... health hazards. While tobacco is still the nation's principal ... obesity was running a close second. ,For ... Corp. economist Roland Sturm used data from two national ...
... human diet mean people today are more at risk of ... the University of Newcastle believe that changes to the way ... anti-cancer agents. ,The researchers are working on a ... stomach cancer. They are carrying out two trials on people ...
... in hospital who smoke and have a history of ... surveyed almost 400 patients// to find if there was ... classified them into four groups:current tobacco use only, history ... ,The patients with both current tobacco use and past ...
... According to researchers reducing weight and increasing exercise cut ... have elevated blood sugar are known to be at ... serious even life-threatening complications, it would be very useful ... individuals avoid the disease. ,Researchers for the ...
... longtime sufferers. New research shows that a combination of ... the severity and frequency of chronic tension headches, which ... people with mild to moderate head pain that occurs ... six months. Although antidepressants require a prescription, they may ...
Cached Medicine News:
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Symphony family of Pacemakers, Ela presents the ... lighter than a passport, will take your ... technologies, and delivering powerful monitoring. ELA ... dual-chamber and atrial tracking modes in patients ...
Medicine Products: